ASCO21 data for bispecific checkpoints bode well for coming wave of therapies

Data are beginning to emerge at ASCO21 from the growing pipeline of bispecific checkpoints, and the readouts provide early evidence that the next-generation antibody structure may produce immuno-oncology’s next wave of therapies. 

At least six clinical data readouts on bispecific checkpoints will be presented at the American Society of Clinical Oncology (ASCO) meeting this weekend, the most advanced of which point to promising efficacy against solid tumors that haven’t responded well to standard checkpoint blockers. ...